Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Benzinga · 1d ago
Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.